Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi®)

Assessment Status Rapid review complete
Drug Sofosbuvir/Velpatasvir/Voxilaprevir
Brand Vosevi®
Indication For the treatment of chronic hepatitis C virus (HCV) infection in adults – pangenotypic i.e. all genotypes (GT1, 2, 3, 4, 5 and 6).
Assessment Process
Rapid review commissioned 19/09/2017
Rapid review completed 15/11/2017
Rapid review outcome Full pharmacoeconomic assessment not recommended